TScan Therapeutics (TCRX) Change in Acquisitions & Divestments (2024 - 2025)

TScan Therapeutics' (TCRX) quarterly Change in Acquisitions & Divestments came in at $15.0 million in Q4 2025, down 80.14% year-on-year from $75.5 million in Q4 2024, and down 55.88% on a QoQ basis from $34.0 million in Q3 2025.

TScan Therapeutics (TCRX) Change in Acquisitions & Divestments (2024 - 2025) Analysis & Trends

TScan Therapeutics (TCRX) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $15.0 million in Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 80.14% year-over-year to $15.0 million in Q4 2025; TTM through Dec 2025 was $201.2 million, a 4.46% increase from a year earlier, with the FY2025 full-year figure at $201.2 million, up 4.46% from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 stood at $15.0 million, down from $34.0 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for TCRX reached as high as $76.2 million in Q2 2025 and fell as low as $15.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 TScan Therapeutics 100.59 Mn -27.47 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 15.00 Mn
Dec 31, 2025 15.00 Mn
Sep 30, 2025 34.00 Mn
Sep 30, 2025 34.00 Mn
Jun 30, 2025 76.25 Mn
Jun 30, 2025 76.25 Mn
Mar 31, 2025 76.00 Mn
Mar 31, 2025 76.00 Mn
Dec 31, 2024 75.51 Mn
Dec 31, 2024 75.51 Mn
Sep 30, 2024 56.00 Mn
Sep 30, 2024 56.00 Mn
Jun 30, 2024 15.50 Mn
Jun 30, 2024 15.50 Mn
Mar 31, 2024 45.65 Mn
Mar 31, 2024 45.65 Mn